肝素及其类似物的非抗凝作用。

The non-anticoagulant promise of heparin and its mimetics.

机构信息

Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London, SE1 9NH, UK.

出版信息

Curr Opin Pharmacol. 2019 Jun;46:50-54. doi: 10.1016/j.coph.2019.03.009. Epub 2019 Apr 19.

DOI:10.1016/j.coph.2019.03.009

Abstract

Heparin, the widely used anticoagulant and antithrombotic polysaccharide, has other potential therapeutic uses that arise from its similarity to heparan sulfate. This review provides a brief overview of the most recent developments in this field, paying particular respect to pulmonary and respiratory pharmacology. It has often been said that heparin, with its mimetics and derivatives, shows great promise in the treatment of inflammatory, infectious, and malignant conditions. Difficulties are encountered, however, in translating this promise into worthwhile treatment strategies for patients in some conditions. Several clinical trials of low molecular weight heparins as adjuvant therapy to standard treatment of lung cancers have recently provided no evidence to support the supposed beneficial effects of low molecular weight heparin.

摘要

肝素是一种广泛应用的抗凝和抗血栓多糖，其与硫酸乙酰肝素的相似性使其具有其他潜在的治疗用途。本综述简要概述了该领域的最新进展，特别关注肺部和呼吸药理学。人们常说，肝素及其类似物和衍生物在治疗炎症、感染和恶性疾病方面具有广阔的前景。然而，在将这种前景转化为某些情况下患者的有效治疗策略时，会遇到困难。最近几项低分子量肝素作为肺癌标准治疗辅助治疗的临床试验没有提供证据支持低分子量肝素的预期有益效果。